Literature DB >> 10815826

MET oncogene aberrant expression in canine osteosarcoma.

R Ferracini1, P Angelini, E Cagliero, A Linari, M Martano, J Wunder, P Buracco.   

Abstract

The objective of this study was to investigate the role of the MET oncogene in canine osteosarcoma. Seven large-breed dogs affected by spontaneous skeletal osteosarcoma underwent en bloc tumor excision. Total RNA was extracted from frozen tumor samples and assessed for expression of the MET oncogene by Northern blot analysis. Five of seven biopsy samples expressed high levels of the MET oncogene; its expression in the primary tumors was comparable with that previously identified in primary osteosarcomas in humans. A lung metastasis from one of the dogs expressed MET at a higher level than did its primary tumor. Spontaneously arising osteosarcoma in dogs clinically and pathologically mimics the corresponding disease in humans. We previously demonstrated that the MET oncogene was aberrantly expressed in a high percentage of human osteosarcomas. The results of the current study also provide a molecular parallel between the tumors in dogs and humans. This in vivo model may be helpful in evaluating new strategies for therapy against osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815826     DOI: 10.1002/jor.1100180213

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  7 in total

1.  Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.

Authors:  Melissa Paoloni; Sean Davis; Susan Lana; Stephen Withrow; Luca Sangiorgi; Piero Picci; Stephen Hewitt; Timothy Triche; Paul Meltzer; Chand Khanna
Journal:  BMC Genomics       Date:  2009-12-23       Impact factor: 3.969

Review 2.  Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

Authors:  Giovanna Finocchiaro; Luca Toschi; Letizia Gianoncelli; Marina Baretti; Armando Santoro
Journal:  Ann Transl Med       Date:  2015-04

3.  miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met.

Authors:  Guangfeng Niu; Bin Li; Jianmin Sun; Li Sun
Journal:  Cell Prolif       Date:  2015-04-16       Impact factor: 6.831

4.  c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

Authors:  E Gregory MacEwen; Jon Kutzke; Jennifer Carew; Josep Pastor; Julie A Schmidt; Rachel Tsan; Douglas H Thamm; Robert Radinsky
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.

Authors:  Stacey L Fossey; Misty D Bear; William C Kisseberth; Michael Pennell; Cheryl A London
Journal:  BMC Cancer       Date:  2011-04-11       Impact factor: 4.430

6.  Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts.

Authors:  Milan Milovancev; Ian Hilgart-Martiszus; Michael J McNamara; Cheri P Goodall; Bernard Seguin; Shay Bracha; Samanthi I Wickramasekara
Journal:  BMC Vet Res       Date:  2013-06-13       Impact factor: 2.741

7.  miR-106B-25 Cluster expression: a comparative human and canine osteosarcoma study.

Authors:  Leonardo Leonardi; Maria Serena Benassi; Serena Pollino; Carmen Locaputo; Laura Pazzaglia
Journal:  Vet Rec Open       Date:  2020-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.